Skip to main content

Neurocrine Biosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic

Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.

Did you know?

Earnings per share grew at a 50.0% CAGR.

Current Price

$131.78

+0.08%

GoodMoat Value

$213.39

61.9% undervalued
Profile
Valuation (TTM)
Market Cap$13.14B
P/E27.45
EV
P/B4.04
Shares Out99.71M
P/Sales4.59
Revenue$2.86B
EV/EBITDA15.84

Neurocrine Biosciences Inc (NBIX) Valuation

NBIX Fair Value Estimate

$213.3961.9% undervalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

NBIX Valuation Metrics

FCF$748.70M
FCF Growth Rate33.49%
EPS Growth (CAGR)50.00%
WACC10.00%

NBIX Valuation & Fair Value Analysis

Neurocrine Biosciences Inc (NBIX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Neurocrine Biosciences Inc is $213.39. The current stock price is $131.78, suggesting the stock is 61.9% undervalued.

The price-to-earnings (P/E) ratio is 27.45. Price-to-book ratio is 4.04. Price-to-sales ratio is 4.59. Enterprise value to EBITDA is 15.84. PEG ratio is 0.55.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Neurocrine Biosciences Inc's intrinsic value.